Skip to Content

2024 US Drug Distribution Landscape Report

The big three drug distributors are forecasted to enjoy mid-single digit growth through 2028

The US population is aging, and with it, the need for more prescriptions. Americans aged 65+ spend over a third of total drug expenditures, and our analysts expect drug distributor sales to benefit as Americans continue to grow older. In fact, the largest drug distributors are expected to surpass $1 trillion in sales in the next five years. What should investors know?

Our latest report on the US drug distribution landscape investigates key industry themes, market share and concentration, deep dives into generic, branded, and specialty drugs, industry outlooks, ESG considerations, and more.

Download the report today to discover how drug distribution stocks can bolster your clients’ investment strategies.

What's inside

  • How customer switching costs and generic drugs affect drug distributor firms’ economic moats 
  • The relationship between prescription volume and drug prices for branded, generic, and specialty drugs 
  • Which factors—like biosimilars and GLP-1s—are expected to drive industry growth in the next five years

Get the report